Objective To investigate the effect of chemotherapy-induced nausea and vomiting and adverse reaction of Aprepitant utilized in patient with lung cancer. Methods 160 patients were randomly divided into the group A, which was given Aprepitant, tropisetron and hexadecadrol, and the group B given ropisetron and hexadec-adrol. Nausea, vomiting and treat correlated adverse reaction were compared between the two groups. Results The extents of reaction of nausea and vomiting in the group A were obviously lower than those in the group B (P<0. 05). The valid control rates of nausea and vomiting were 96. 2% and 97. 5% in the group A, which were obviously higher than those in the group B (81. 2% and 83. 8%) (P<0. 05). There was no significant difference in the main adverse reactions such as anorexia, constipation, fatigue, hiccough, dizziness and dry mouth between the two groups. Con-clusion Aprepitant can ease off the adverse reactions such as nausea and vomiting induced by chemotherapy in the treatment of patient with lung cancer.%目的：观察肺癌患者采用阿瑞匹坦口服，化疗诱导性恶心和呕吐的效果及不良反应。方法采用随机对照，将160例患者随机分为A和B两组，阿瑞匹坦组( A组)采用阿瑞匹坦、托烷司琼联合地塞米松，标准方案组(B组)采用托烷司琼联合地塞米松，两组患者比较恶心、呕吐及治疗相关不良反应的发生率。结果阿瑞匹坦组患者恶心( Z =-2．028)及呕吐( Z =-2．151)反应程度明显低于和标准方案组( P <0．05)；阿瑞匹坦组对恶心、呕吐的有效控制率(96．2%、97．5%)明显高于标准方案组(81．2%、83．8%)(P<0．05)，差异有统计学意义。两种方案其它主要不良反应如厌食、便秘、疲倦、呃逆、头晕、口干等发生率差异均无统计学意义(P>0．05)。结论肺癌患者化疗服用阿瑞匹坦胶囊，能减轻化疗引起的恶心、呕吐等不良反应，而且具有很好的耐受性。
展开▼
